Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



An Animal of a Quarter

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Unlike Pfizer (NYSE: PFE  ) , which had a rough quarter as it struggled with Lipitor exclusivity, the pharma's animal-health spinoff Zoetis (NYSE: ZTS  ) turned in a solid first quarter.

Revenue was up 4% year over year, which would have been 5% if the dollar hadn't strengthened against other currencies. Treatments for companion animals, mostly dogs and cats, helped raise revenue with sales up 8%.

Part of the benefit came from a competitor's supply issue that has been resolved. Pfizer didn't say which competitor it was, but we can guess it probably wasn't Merck (NYSE: MRK  ) ; sales of its animal health division were up 4% at constant currency, and the company cited "strong performance in companion animal products" as part of the reason for the increase. Elanco, Eli Lilly's (NYSE: LLY  ) animal health division, didn't do quite as well, with sales up just 2%, but the slow growth seems to mostly be due to animal food products that don't compete with Zoetis. The other two big players in the animal health space -- Bayer and Sanofi -- haven't reported yet.

Zoetis' livestock products were a little light, up just 3%, dragged down by treatments for cattle. The drought has caused farmers to reduce their herds. It could take a couple of years to get the cow population back to the same levels. They don't reproduce nearly as quickly as something like chickens.

On the earnings side, adjusted earnings per share was up 20% year over year. The disparity between revenue growth and earnings growth is quite dramatic, but doesn't seem to be attributable to any one area. On an adjusted basis for one-time items, the company was able to cut expenses across the board. Adjusted gross margins increased a little, from 62.9% last year, to 63.5% this year. SG&A and R&D expenses also fell year over year.

Increasing revenue, decreasing expenses, what more could investors ask for?

Should Pfizer have let Zoetis go?
Pfizer would have been better off with Zoetis, but it wouldn't have changed Pfizer's earnings number all that much, because Pfizer still owns 80.2% of Zoetis. It includes that fraction of Zoetis' earnings in its earnings report.

More importantly, the decision to spin out Zoetis wasn't to benefit Pfizer (the company), but Pfizer's shareholders. The company got $6 billion from the IPO and, if shares continue to rise -- Zoetis is trading more than 25% higher than its IPO price -- it can sell additional shares and raise more capital for buybacks and beefing up the pipeline.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013, and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2402065, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:23:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:01 PM
LLY $80.88 Up +1.36 +1.71%
Eli Lilly and Co. CAPS Rating: ***
MRK $62.57 Up +0.42 +0.68%
Merck and Co. CAPS Rating: ****
PFE $33.83 Up +0.19 +0.56%
Pfizer CAPS Rating: ****